Tag: off the shelf gene therapy for rare disease development
2024-2025 Guide to AI in Rare & Ultra-Rare Disease Gene Therapy: FDA Incentives, Next-Gen Pipeline, Off-the-Shelf & Single-Dose Multi-Disease Research Updates
Updated October 2024 | Google Partner-certified biotech regulatory strategy | 12+ years rare disease therapy approval experience. Per FDA 2024 Rare Disease Report, Biotechnology Innovation Organization 2024, and NIH 2024 data, 87% of ultra-rare disease patients lack FDA-approved treatment, but AI integration cuts gene therapy development timelines by 42% and boosts program ROI by 38%.